Relmada Therapeutics, Inc. filed a current report on November 16, 2026, announcing the appointment of Jørn Skibsted Jakobsen, MD, PhD, as its Chief Development Officer.

Key Highlights

  • New Executive Appointment: Jørn Skibsted Jakobsen, MD, PhD, was named Chief Development Officer of Relmada Therapeutics, Inc.
  • Announcement Date: The press release announcing the appointment was issued on November 16, 2026.
  • Disclosure Channel: The appointment was disclosed under Regulation FD and furnished as Exhibit 99.1 to the current report.
  • Signing Officer: The report was signed by Sergio Traversa, Chief Executive Officer, on behalf of the registrant.
  • Registrant: Relmada Therapeutics, Inc. is a Nevada-incorporated company listed on NASDAQ:RLMD with common stock carrying a $0.001 par value per share.

Relmada Therapeutics Adds Senior Clinical Leadership with Jakobsen Appointment

According to the filing, Relmada Therapeutics, Inc. issued a press release on November 16, 2026, announcing the appointment of Jørn Skibsted Jakobsen, MD, PhD, to the role of Chief Development Officer. The company, headquartered at 2222 Ponce de Leon Blvd., Floor 3, Coral Gables, FL 33134, is a Nevada-incorporated biopharmaceutical registrant listed on the Nasdaq Capital Market under the ticker symbol RLMD, with common stock carrying a par value of $0.001 per share.

The filing disclosed the appointment under Item 7.01, Regulation FD Disclosure. The press release was furnished with the current report as Exhibit 99.1. As the company noted in the filing, the information in Item 7.01 and in Exhibit 99.1 is "deemed to be 'furnished' and shall not be deemed to be 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934." Accordingly, the disclosure is not subject to the liabilities of that section and is not incorporated by reference into other filings under the Exchange Act or the Securities Act of 1933, unless expressly set forth by specific reference.

The current report was signed by Sergio Traversa, in his capacity as Chief Executive Officer, on behalf of Relmada Therapeutics, Inc. No financial statements were included in this filing. The only exhibits listed were Exhibit 99.1, the press release dated November 16, 2026, and Exhibit 104, the Cover Page Interactive Data File embedded within the Inline XBRL document.

What Was Disclosed

Relmada Therapeutics, Inc. reported the appointment of Jørn Skibsted Jakobsen, MD, PhD, as Chief Development Officer via a Regulation FD press release furnished on November 16, 2026, and signed by CEO Sergio Traversa.